Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.freeradbiomed.2021.10.019
Title: Low plasma ergothioneine levels are associated with neurodegeneration and cerebrovascular disease in dementia
Authors: Wu, Liu-Yun
Cheah, Irwin K
Chong, Joyce Ruifen
Chai, Yuek Ling 
Tan, Jia Yun
Hilal, Saima 
Vrooman, Henri
Chen, Christopher P 
Halliwell, Barry 
Lai, Mitchell KP 
Keywords: Science & Technology
Life Sciences & Biomedicine
Biochemistry & Molecular Biology
Endocrinology & Metabolism
Alzheimer's disease
Biomarkers
Cerebrovascular diseases
Ergothioneine
Neurodegeneration
Vascular dementia
WHITE-MATTER HYPERINTENSITIES
VASCULAR RISK-FACTORS
ALZHEIMERS-DISEASE
OXIDATIVE STRESS
COGNITIVE IMPAIRMENT
PARKINSONS-DISEASE
IN-VITRO
BIOMARKERS
PROTECTS
HIPPOCAMPAL
Issue Date: 27-Oct-2021
Publisher: ELSEVIER SCIENCE INC
Citation: Wu, Liu-Yun, Cheah, Irwin K, Chong, Joyce Ruifen, Chai, Yuek Ling, Tan, Jia Yun, Hilal, Saima, Vrooman, Henri, Chen, Christopher P, Halliwell, Barry, Lai, Mitchell KP (2021-10-27). Low plasma ergothioneine levels are associated with neurodegeneration and cerebrovascular disease in dementia. FREE RADICAL BIOLOGY AND MEDICINE 177 : 201-211. ScholarBank@NUS Repository. https://doi.org/10.1016/j.freeradbiomed.2021.10.019
Abstract: Ergothioneine (ET) is a dietary amino-thione with strong antioxidant and cytoprotective properties and has possible therapeutic potential for neurodegenerative and vascular diseases. Decreased blood concentrations of ET have been found in patients with mild cognitive impairment, but its status in neurodegenerative and vascular dementias is currently unclear. To address this, a cross-sectional study was conducted on 496 participants, consisting of 88 with no cognitive impairment (NCI), 201 with cognitive impairment, no dementia (CIND) as well as 207 with dementia, of whom 160 have Alzheimer's Disease (AD) and 47 have vascular dementia. All subjects underwent blood-draw, neuropsychological assessments, as well as neuroimaging assessments of cerebrovascular diseases (CeVD) and brain atrophy. Plasma ET as well as its metabolite L-hercynine were measured using high sensitivity liquid chromatography tandem-mass spectrometry (LC-MS/MS). Plasma ET concentrations were lowest in dementia (p < 0.001 vs. NCI and CIND), with intermediate levels in CIND (p < 0.001 vs. NCI). A significant increase in L-hercynine to ET ratio was also observed in dementia (p < 0.01 vs. NCI). In multivariate models adjusted for demographic and vascular risk factors, lower levels of ET were significantly associated with dementia both with or without CeVD, while ET associations with CIND were significant only in the presence of CeVD. Furthermore, lower ET levels were also associated with white matter hyperintensities and brain atrophy markers (reduced global cortical thickness and hippocampal volumes). The incremental decreases in ET levels along the CIND-dementia clinical continuum suggest that low levels of ET are associated with disease severity and could be a potential biomarker for cognitive impairment. Deficiency of ET may contribute towards neurodegeneration- and CeVD-associated cognitive impairments, possibly via the exacerbation of oxidative stress in these conditions.
Source Title: FREE RADICAL BIOLOGY AND MEDICINE
URI: https://scholarbank.nus.edu.sg/handle/10635/218879
ISSN: 08915849
18734596
DOI: 10.1016/j.freeradbiomed.2021.10.019
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Low plasma ET assoc with neurodegeneration.pdfPublished version4.1 MBAdobe PDF

CLOSED

None
FRB_15394 Proof.pdfAccepted version1.32 MBAdobe PDF

OPEN

None Available on 27-10-2022

SCOPUSTM   
Citations

11
checked on Sep 23, 2022

Page view(s)

69
checked on Sep 22, 2022

Download(s)

2
checked on Sep 22, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.